2025
EVALUATING CLINICAL OUTCOMES AND THE ROLE OF NEOADJUVANT CHEMOTHERAPY IN PLASMACYTOID UROTHELIAL CARCINOMA: INSIGHTS FROM A COMBINED NATIONAL AND INSTITUTIONAL SERIES
Rahman S, Kong V, Jalfon M, Hesse D, Kim J, Wright J, Adeniran A, Humphrey P, Martin D, Ghali F. EVALUATING CLINICAL OUTCOMES AND THE ROLE OF NEOADJUVANT CHEMOTHERAPY IN PLASMACYTOID UROTHELIAL CARCINOMA: INSIGHTS FROM A COMBINED NATIONAL AND INSTITUTIONAL SERIES. Urologic Oncology Seminars And Original Investigations 2025, 43: 43. DOI: 10.1016/j.urolonc.2024.12.109.Peer-Reviewed Original ResearchPlasmacytoid urothelial carcinomaNational Cancer DatabaseMedian overall survivalNeoadjuvant chemotherapyUrothelial carcinomaOverall survivalImpact of neoadjuvant chemotherapyResponse to current therapiesCharacterize treatment patternsPrimary treatment typeCox proportional hazards analysisSite of metastasisEvaluate clinical outcomesProportional hazards analysisBorderline statistical significancePT0 rateOS benefitHistological subtypesCancer DatabaseClinical stageClinical outcomesTreatment patternsCurrent therapiesInstitutional experiencePrimary outcomeEvaluating the therapeutic role of lymph node dissection in variant histology bladder cancer.
Rahman S, Hesse D, Jalfon M, Kong V, Ghali F. Evaluating the therapeutic role of lymph node dissection in variant histology bladder cancer. Journal Of Clinical Oncology 2025, 43: 749-749. DOI: 10.1200/jco.2025.43.5_suppl.749.Peer-Reviewed Original ResearchLymph node dissectionVariant histology bladder cancerRadical cystectomyBladder cancerNodal dissectionNode dissectionSurvival benefit of lymph node dissectionAssociated with lymph node dissectionBenefit of lymph node dissectionImpact of lymph node dissectionLymph node dissection statusPathological nodal statusCox proportional hazards analysisNational Cancer DatabaseUrothelial bladder cancerKaplan Meier analysisCox proportional hazards regressionProportional hazards analysisProportional hazards regressionNo-LND groupDegree of therapeutic benefitNeuroendocrine subtypeSarcomatoid histologyT3/4 diseaseUC histology
2024
Evaluating Treatment Patterns and the Role of Neoadjuvant Chemotherapy in Plasmacytoid Urothelial Carcinoma: Insights from a Combined National and Institutional Series
Rahman S, Kong V, Jalfon M, Hesse D, Kim J, Wright J, Adeniran A, Humphrey P, Martin D, Ghali F. Evaluating Treatment Patterns and the Role of Neoadjuvant Chemotherapy in Plasmacytoid Urothelial Carcinoma: Insights from a Combined National and Institutional Series. Cancers 2024, 16: 3050. PMID: 39272908, PMCID: PMC11394101, DOI: 10.3390/cancers16173050.Peer-Reviewed Original ResearchPlasmacytoid urothelial carcinomaMedian overall survivalNeoadjuvant chemotherapyUrothelial carcinomaOverall survivalTreatment patternsReceipt of neoadjuvant chemotherapyResponse to current therapiesCharacterize treatment patternsCox proportional hazards analysisEvaluate treatment patternsSite of metastasisProportional hazards analysisPT0 rateOS benefitHistological subtypesClinical stageCurrent therapiesInstitutional experiencePrimary outcomeNCDBTreatment trendsEffective treatmentPatientsCarcinoma
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply